Therefore, not only therapies targeting eNOS and/or TNFα, but also extracellular therapeutic strategies targeting GM1 may be useful for prevention and cure of vascular insulin resistance, although further studies are required to evaluate the effects of GM1 systemic targeting. The gene discussed is TNF; the disease is Insulin resistance.